Pacira BioSciences, Inc. Common Stock

PCRXNASDAQUSD
22.75 USD
0.08 (0.35%)AT CLOSE (11:59 AM EDT)
22.73
0.02 (0.09%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
22.73
0.02 (0.09%)
🔴Market: CLOSED
Open?$22.92
High?$23.37
Low?$22.58
Prev. Close?$22.67
Volume?402.7K
Avg. Volume?564.0K
VWAP?$22.90
Rel. Volume?0.71x
Bid / Ask
Bid?$20.28 × 200
Ask?$27.25 × 5.0K
Spread?$6.97
Midpoint?$23.77
Valuation & Ratios
Market Cap?895.2M
Shares Out?39.3M
Float?37.9M
Float %?93.7%
P/E Ratio?174.22
P/B Ratio?1.37
EPS?$0.13
Dividend?0.00%
Ex-Dividend?N/A

Shares of Pacira BioSciences, Inc. Common Stock (PCRX) are trading at $22.75. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest PCRX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Employees
829
Market Cap
895.2M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2011-02-03
Address
2000 SIERRA POINT PARKWAY
BRISBANE, CA 94005
Phone: 650-242-8052
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bearish(-3/3)
Medium-Term (Wave)? Bearish(-2/3)
Short-Term (Ripple)? Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
29
Momentum?
35
Short Sent.?
24
Piotroski F-Score?4/9Mixed
Altman Z-Score?1.82Grey
Confidence?75%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?18.42%High
Short Interest?7.0M
Days to Cover?10.3
Free Float37.9M
Avg Daily Volume680.5K
Settlement Date2026-05-15
Financial Health
Current Ratio?4.73Strong
Quick Ratio?3.35Strong
Cash Ratio?1.33Strong
Debt/Equity?0.56Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
89/100
P/E?
Peers
100
S&P
3
174.2PRICEY
P/B?
Peers
100
S&P
90
1.37CHEAP
P/S?
Peers
100
S&P
83
1.22CHEAP
P/FCF?
Peers
100
S&P
97
6.8CHEAP
EV/EBITDA?
Peers
100
S&P
83
9.7CHEAP
EV/Sales?
Peers
100
S&P
83
1.52CHEAP
Returns & Efficiency
ROE?
Peers
50
S&P
16
0.8%WEAK
ROA?
Peers
50
S&P
9
0.4%WEAK
Cash Flow & Enterprise
FCF?$132.7M
Enterprise Value?$1.1B
Fundamentals ratios updated end of day